KR20010110001A - Cosmetics composition containing Psoralea corylifolia L. extracts - Google Patents
Cosmetics composition containing Psoralea corylifolia L. extracts Download PDFInfo
- Publication number
- KR20010110001A KR20010110001A KR1020000030873A KR20000030873A KR20010110001A KR 20010110001 A KR20010110001 A KR 20010110001A KR 1020000030873 A KR1020000030873 A KR 1020000030873A KR 20000030873 A KR20000030873 A KR 20000030873A KR 20010110001 A KR20010110001 A KR 20010110001A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hazelnut
- cosmetic composition
- hazelnut extract
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 화장료 조성물에 관한 것으로, 개암풀 추출물을 함유하는 것을 특징으로 하며, 본 발명의 화장료 조성물은 개암풀추출물에 의한 세포증식효과, 콜라겐 합성효과 및 히아루론산 합성 효과로 인하여 여성호르몬의 결핍으로 인한 피부노화를 억제할 수 있다.The present invention relates to a cosmetic composition, characterized in that it contains hazelnut extract, the cosmetic composition of the present invention due to the lack of female hormones due to the cell growth effect, collagen synthesis effect and hyaluronic acid synthesis effect by hazelnut extract It can suppress skin aging.
Description
본 발명은 개암풀(Phaseolus vulgaris L.)의 열매 또는 종자로부터 추출한 물질(이후로는 이를 통칭하여 "개암풀 추출물"이라고도 합니다.)을 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing a substance extracted from the fruit or seed of the hazelnut (Phaseolus vulgaris L.) (hereinafter also referred to collectively as "hazelnut extract").
화장품 관련 분야에서 피부의 노화를 억제하기 위하여 극복하여야 할 과제 중 주름생성 억제 또는 주름개선은 가장 중요한 문제이다.In the field of cosmetics, the most important problem is to reduce wrinkle formation or to improve wrinkles among the problems to be overcome in order to suppress skin aging.
여성의 피부는 남성의 피부와는 달리 특징적으로 탄력적이고 부드럽고 촉촉하며, 피지의 분비가 적으며 그리고 털이 적은데, 그 이유는 여성호르몬의 영향 때문이다. 여성호르몬인 에스트로겐(estrogen)의 피부에 대한 생리적 작용을 살펴보면 진피(dermis)에 있는 섬유아세포(fibroblast)를 자극하여 콜라겐(collagen)합성과 콜라겐 신진대사를 촉진시키며 또한 피부수분유지에 매우 중요한 히아루론산(Hyaluronic acid)합성을 촉진시킴으로 피부에 탄력성, 부드러움, 유연성 및 보습성을 부여한다. 표피(epidermis)에 있는 기저세포(basal layer cell)의증식효과(proliferation effect)를 증가시켜 표피를 좀더 두텁게 하여 피부 세포조직을 강화시킨다. 그리고 피지선(sebaceous gland)을 조절하여 피지선의 성장을 억제하여 피지(sebum)의 생성을 감소시키며, 털의 성장속도를 낮추어 털이 가늘고 짧게 유지시킨다. 특히 콜라겐(collagen)의 대사에 관여하여 콜라겐의 오버글리케이션(over-glycation)을 억제하고 포스트트랜스레이셔날 모디피케이션(post-translational modification)을 유도하며 콜라겐 분해효소인 콜라게나제(collagenase)의 발현을 조절하여 콜라겐의 분해를 억제한다. 이와 같이 여성호르몬의 피부에 대한 주 기능은 피부 활동을 강화시키며 피부를 부드럽고 탄력적이며 유연하게 하는 것이다.Unlike the skin of men, women's skin is characteristically elastic, soft and moist, sebum secretion and hairless because of the effect of female hormones. The physiological effects of the female hormone estrogen on the skin suggest that it stimulates fibroblasts in the dermis to promote collagen synthesis and collagen metabolism and is very important for skin moisture retention. Hyaluronic acid) Promotes synthesis, giving skin elasticity, softness, flexibility and moisturizing properties. It increases the proliferation effect of basal layer cells in the epidermis, making the epidermis thicker to strengthen skin tissue. And by controlling the sebaceous gland (sebaceous gland) to suppress the growth of sebaceous gland to reduce the production of sebum (sebum), to lower the hair growth rate to keep the hair thin and short. In particular, it is involved in collagen metabolism, inhibits over-glycation of collagen, induces post-translational modification, and induces collagenase, a collagen degrading enzyme. Regulates expression to inhibit degradation of collagen. As such, the main function of female hormone on skin is to strengthen skin activity and make skin soft, elastic and supple.
그러나 여성호르몬의 분비장소인 생식기관이 나이가 들어감에 따라 점차 기능이 퇴화되어가다가 생산기능이 사라지는 시점인 폐경기(menopause)를 전후하여 여성호르몬의 생성인 중지된다. 생식능력이 유지되는 기관에서는 난소에 의한 에스트로겐(estrogen) 생성으로 호르몬의 균형이 유지되지만 폐경기에는 여성호르몬의 생성이 중지되어 호르몬의 균형이 파괴 되면서 남성호르몬인 테스토스테론(testosterone)의 비 경쟁적인 영향을 받게되어 여성호르몬 결핍에 따른 내분비성 노화(Endocrine ageing)가 촉진된다. 내분비성 노화는 피부노화의 일종으로 폐경기시 나타나는 생리적인 피부 노화이다.However, as the reproductive organs, the secretory sites of female hormones, age, the function gradually deteriorates, and the production of female hormones is stopped before and after menopause. In organs that maintain fertility, hormonal balance is maintained by ovarian estrogen production, but during menopause, the production of female hormones stops, and the balance of hormones is destroyed. Endocrine ageing caused by female hormone deficiency is promoted. Endocrine aging is a type of skin aging that is physiological skin aging that occurs during menopause.
여성호르몬 결핍으로 인하여 피부의 변화가 일어나는데 대표적인 현상이 피부건조이다. 여성호르몬의 결핍으로 섬유아세포에서는 콜라겐, 탄력섬유(elastic fiber) 등의 생성이 억제되어, 피부가 얇아지면 피부의 탄력이 감소한다. 또한 히아루론산(hyaluronic acid)의 합성장소로 피부의 수분유지기능이 약화된다. 그리고 콜라겐 글리케이션(collagen glycation)이 증가하여 콜라겐의 교차결합이 증가하여 피부가 경화(Sclerosis)되어 탄력이 감소하게 된다.Female hormone deficiency causes skin changes, a typical phenomenon of skin dryness. The lack of female hormone in the fibroblasts inhibits the production of collagen, elastic fibers (elastic fiber, etc.), the skin becomes thinner, the elasticity of the skin is reduced. It is also a synthetic place of hyaluronic acid, which weakens the skin's water retention function. And collagen glycation (collagen glycation) is increased to increase the cross-linking of collagen, the skin is hardened (Sclerosis) is reduced elasticity.
여성호르몬의 결핍으로 인한 피부노화를 억제하기 위한 해결 방법에 대한 연구 결과들이 보고되고 있다. 호르몬 대체요법(Hormone Replacement Therapy)이 대표적인 것으로 부족한 여성호르몬을 직접 공급하는 것이다. 여성호르몬을 공급하였을 경우 콜라겐 합성의 증가, 히아루론산(hyaluronic acid) 합성의 증가 및 표피세포의 증식효과로 표피의 두께가 증가하는 등 뚜렷한 효과가 입증되고 있다. 그러나 화장품에서는 여성호르몬을 직접적으로 사용하지 못하고 있기 때문에 다른 방법들이 강구되고 있다. 화장품적으로 고려되는 부분은 보습제, 노화억제물질, 자유라디칼 소거물질 및 자외선 차단제 등을 처리하여 직접적인 여성호르몬 결핍에 따른 대처방안이 아니라 피부노화의 일반적 억제물질을 이용한 간접적인 대처방안이다.The results of research on a solution for suppressing skin aging due to the deficiency of female hormone have been reported. Hormone Replacement Therapy is a typical supply of scarce female hormones. In the case of supplying female hormones, there are prominent effects such as increased collagen synthesis, hyaluronic acid synthesis, and epidermal cell proliferation, resulting in increased epidermal thickness. However, cosmetics do not use female hormones directly, so other methods have been taken. Cosmetic considerations are not indirect treatment of skin hormonal deficiency by treating moisturizers, aging inhibitors, free radical scavengers and sunscreens, but indirect treatments using general inhibitors of skin aging.
폐경기 전후로 하여 급격히 노화가 진행되는 여성피부를 개선하기 위하여 여성호르몬과 유사기능을 갖는 물질의 개발이 중요하다. 피부노화를 억제하기 위한 화장품적인 시각에서 여성호르몬 유사물질은 콜라겐합성과 히아루론산 합성증진효과를 갖는 물질이다.In order to improve women's skin rapidly progressing before and after menopause, it is important to develop a substance having a similar function with female hormones. From the cosmetic point of view to suppress skin aging, female hormone-like substance is a substance having collagen synthesis and hyaluronic acid synthesis promoting effect.
따라서 본 발명은 콜라겐 합성과 히아루론산 합성 증진 효과를 갖는 새로운 화장료 조성물을 제공하는 것을 목적으로 한다.Therefore, an object of the present invention is to provide a new cosmetic composition having collagen synthesis and hyaluronic acid synthesis enhancing effect.
본 발명자들은 식물로부터 여성호르몬 유사물질을 개발하기 위하여 우리나라에서 자생하는 생약에 대한 탐색연구를 수행하는 중에, 개암풀 추출물이 세포증식효과, 콜라겐 합성효과 및 히아루론산 합성 효과가 매우 우수함을 알게되어 본 발명을 완성하게 된 것이다.The inventors of the present invention found that the hazelnut extract was very excellent in cell proliferation effect, collagen synthesis effect and hyaluronic acid synthesis effect during the exploratory research on the herbal medicines native to Korea to develop female hormone-like substances from plants. Will be completed.
그러므로 본 발명에 의하면, 개암풀 추출물을 함유하는 화장료 조성물이 제공된다.Therefore, according to this invention, the cosmetic composition containing a hazelnut extract is provided.
또한 본 발명에 의하면, 개암풀 추출물을 전체 조성물의 건조중량기준으로 0.05∼10.0중량% 함유하는 화장료 조성물이 제공된다.Moreover, according to this invention, the cosmetic composition containing 0.05-10.0 weight% of hazelnut extract on the dry weight basis of the whole composition is provided.
이하, 본 발명을 바람직한 구현의 방법으로 보다 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in more detail by way of preferred embodiment.
개암풀은 높이 40-90cm 되는 한해살이풀이며, 닭알모양잎이 어긋나게 붙고 노란보라색꽃이 이삭처럼 모여 핀다. 열매는 타원형이고 속에 한 개의 씨가 있다. 열대원산이며, 우리나라에서는 약초로 재배한다.Hazelnut is annual plant 40-90cm high, with egg-shaped leaves alternately attached and yellow purple flowers gather like ears. The fruit is elliptical with one seed in the inside. It is native to the tropics and is grown as a herb in Korea.
본 발명의 화장료 조성물에 첨가되는 개암풀 추출물은 예를 들어 다음과 같은 방법으로 제조될 수 있다.Hazelnut extract added to the cosmetic composition of the present invention can be prepared, for example, in the following manner.
우선, 개암풀의 열매 또는 종자를 건조한 후 정제수로 세척한 다음 건조하여 분말화하고, 분말화된 개암풀 열매 또는 종자의 건조 중량에 대하여 추출 용매를 1∼15배의 양으로 가해 실온에서 1∼15일간 침지(沈漬)시켜 유효 성분을 추출한후, 추출용액을 감압 농축하여 목적하는 개암풀 종자 추출물을 획득할 수 있다. 특별히제한하기 위한 것은 아니지만, 추출용매로서는 물, 메탄올, 에탄올, 아세톤, 에틸아세테이트, 1·3-부틸렌 글리콜(Butylene glycol), 헥산(hexane), 디에틸 에테르(Diethyl ether), 노말 프로판올(n-propanol), 이소-프로판올(Iso-propanol) 및 노말-부탄올(n-butanol)로 이루어진 군에서 선택되는 1종 또는 2종 이상의 혼합물이 바람직하다. 특히 바람직한 추출용매는 물, 메탄올, 에탄올 및 1,3-부틸렌글리콜로 이루어진 군에서 선택되는 1종 또는 2종 이상의 혼합물이다. 또한 특별히 제한하기 위한 것은 아니지만 추출용액의 감압농축에는 냉각 콘덴서가 달린 증류 장치 등을 이용할 수 있다.First, the fruit or seeds of the hazelnuts are dried, washed with purified water and then dried to be powdered, and the extraction solvent is added in an amount of 1 to 15 times the dry weight of the powdered hazelnut fruit or seeds, and then at 1 to room temperature. After soaking for 15 days to extract the active ingredient, the extract solution can be concentrated under reduced pressure to obtain the desired hazelnut seed extract. Although not particularly limited, extraction solvents include water, methanol, ethanol, acetone, ethyl acetate, 1,3-butylene glycol, hexane, diethyl ether, and normal propanol (n). -propanol), iso-propanol, and one or two or more mixtures selected from the group consisting of n-butanol are preferred. Particularly preferred extractant is one, or a mixture of two or more selected from the group consisting of water, methanol, ethanol and 1,3-butylene glycol. Although not particularly limited, a distillation apparatus equipped with a cooling condenser may be used for the vacuum concentration of the extraction solution.
본 조성물에 함유되는 개암풀 추출물은 인체에 적용시 세포증식효과, 콜라겐 합성효과 및 히아루론산 합성 효과를 발현하여, 피부노화를 억제하는 작용을 한다.Hazelnut extract contained in the composition has a function of inhibiting skin aging by expressing a cell proliferation effect, collagen synthesis effect and hyaluronic acid synthesis effect when applied to the human body.
본 발명의 화장료 조성물은 개암풀 추출물을 전체 조성물의 건조중량기준으로 0.05∼10.0중량%의 양으로 함유하는 것이 바람직하다.The cosmetic composition of the present invention preferably contains the hazelnut extract in an amount of 0.05 to 10.0% by weight based on the dry weight of the total composition.
바람직하게 본 발명을 적용할 수 있는 화장료 조성물의 제품형태를 예를 들면, 화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩, 보디 오일 등과 같은 기초제품 화장료; 화운데이션, 립스틱, 마스카라, 메이크업 베이스 등과 같은 색조제품 화장료; 샴푸, 린스, 헤어콘디셔너, 헤어젤 등과 같은 두발제품 화장료 등을 들 수 있다.Preferably, the product form of the cosmetic composition to which the present invention can be applied includes, for example, cosmetics for basic products such as lotion, cream, essence, cleansing foam, cleansing water, pack, body oil, etc .; Color cosmetics such as foundation, lipstick, mascara, makeup base, etc .; Hair cosmetics such as shampoo, conditioner, hair conditioner, hair gel, and the like.
이상 설명한 바와 같은 본 발명의 특징 및 기타의 장점은 후술되는 실시예로부터 보다 명백하게 될 것이다.Features and other advantages of the present invention as described above will become more apparent from the following examples.
실시예 1 내지 21Examples 1 to 21
1. 개암풀 열매 추출물의 제조1. Preparation of Hazelnut Extract
[실시예 1]Example 1
개암풀 열매를 정제수로 세척하고 건조시킨 다음 분쇄하여 개암풀 분말을 준비하였다. 개암풀 분말 1㎏을 물 5ℓ에 넣고 15∼40℃에서 3∼5일간 추출한 후 300메쉬 여과포로 여과하고, 4∼ 15℃에서 7∼10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 여과추출물을 냉각 콘덴서가 달린 증류장치에서 70℃로 감압 농축한 후, 건조하여 개암풀 추출물을 얻었다. 3회평균 추출량은 110.34g(건조중량)이었고, 수율은 11.0±098%이었다.Hazelnut fruit was washed with purified water, dried and ground to prepare hazelnut powder. 1 kg of hazelnut powder was added to 5 L of water, extracted for 3 to 5 days at 15 to 40 ° C., filtered through a 300 mesh filter cloth, left at 4 to 15 ° C. for 7 to 10 days, and then aged at low temperature. It was. The filtrate was concentrated under reduced pressure at 70 ° C. in a distillation apparatus equipped with a cooling condenser and then dried to obtain a hazelnut extract. Three times the average extraction amount was 110.34g (dry weight), the yield was 11.0 ± 098%.
[실시예 2]Example 2
실시예 1과 동일한 방법으로 준비한 개암풀 분말 1㎏을 10% 에탄올 5ℓ에 넣고 냉각 콘덴서가 달린 추출기에서 3일간 추출한 후 300메쉬 여과포로 여과하고 4∼15℃에서 7∼10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 여과추출물은 냉각 콘덴서가 달린 증류장치에서 70℃로 감압 농축하고 건조하여 개암풀 추출물을 얻었다. 3회평균 추출량은 105.4g(건조중량)이었고, 수율은 10.5±0.8%이었다.1 kg of hazelnut powder prepared in the same manner as in Example 1 was added to 5 l of 10% ethanol, extracted in an extractor equipped with a cooling condenser for 3 days, filtered through a 300 mesh filter cloth, and left at 4 to 15 ° C. for 7 to 10 days to be aged at low temperature. It was then filtered through Whatman twice filter paper. The filtrate was concentrated under reduced pressure at 70 ° C. in a distillation apparatus equipped with a cooling condenser and dried to obtain a hazelnut extract. Three times the average extraction amount was 105.4g (dry weight), the yield was 10.5 ± 0.8%.
[실시예 3 내지 21][Examples 3 to 21]
하기 표 1 기재의 용매를 사용하여 실시예 2의 방법으로 추출하여 하기 표 1 기재와 같은 추출 수율로 개암풀 추출물을 얻었다.To extract the hazelnut extract in the same extraction yield as described in Table 1 using the solvent described in Table 1 below.
2. 개암풀 추출물의 세포 증식 효과 실험2. Cell Proliferation Effect of Hazelnut Extract
1) 실험 방법1) Experiment Method
인체 정상 섬유아세포(Human normal fibroblast)를 96웰 마이크로 플레이트(96-well microplate)의 각 웰(well)에 1x104 세포가 되도록 접종하여 디엠이엠(DMEM) 배지에서 24시간 배양한다. 배양 후 실시예 1∼21에서 제조한 개암풀 추출물을 최종 농도 250㎍/㎖ 되도록 조정한 시럼(serum)이 없는 디엠이엠(DMEM) 배지로 교체한 후 24시간 더 배양한다. MTT 용액[3-(4,5-Dimethyl-thiazole-2-yl) 2,5-diphenyl tetrazolium bromide : 5 ㎎/㎖] 10㎕씩 첨가하고 4시간 방치 후, 배지 부분을 버린다. 각 웰당 100㎕의 디메틸 설폭시드 (DMSO :Dimethyl sulfoxide)용액을 가하여 20분간 교반 후 마이크로플레이트 리더 (microplate Reader)로 570㎚에서 흡광도를 측정하였다.Human normal fibroblasts are inoculated to 1x104 cells in each well of a 96-well microplate and incubated in DMEM medium for 24 hours. After incubation, the hazelnut extract prepared in Examples 1 to 21 was replaced with a serum-free DMEM medium adjusted to a final concentration of 250 μg / ml, followed by further incubation for 24 hours. Add 10 µl of MTT solution [3- (4,5-Dimethyl-thiazole-2-yl) 2,5-diphenyl tetrazolium bromide: 5 mg / ml], and leave for 4 hours, and then discard the media. 100 μl of dimethyl sulfoxide (DMSO: dimethyl sulfoxide) solution was added to each well, followed by stirring for 20 minutes, and the absorbance was measured at 570 nm with a microplate reader.
2) 실험 결과2) Experiment result
개암풀 추출물의 세포증식 효과를 하기 식으로 산출하여 그 결과를 표 2에 나타내었다.The cell proliferation effect of hazelnut extract was calculated by the following formula and the results are shown in Table 2.
* 상기 값은 3회 실시 평균값임* The above value is the average of 3 runs
3. 개암풀 추출물의 콜라겐 합성 증진 효과 실험3. Experimental Study of Collagen Synthesis Enhancement Effect of Hazelnut Extract
1) 실험 방법1) Experiment Method
인체정상 섬유아세포(Human Normal fibroblast)를 96-웰 마이크로 플레이트에 접종시키고(2x104 세포/웰) 24시간 배양한다. 배양 후 배지를 시럼이 함유되지않은 디엠이엠(DMEM)으로 교체한다. 이때 여러 농도의 개암풀 추출물을 배지와 함께 넣고 48시간 배양한다. 개암풀추출물은 실시예 8에서 제조한 것을 사용하였다. 배양 마지막 24시간 전에 아스코르빅산 (Ascorbic acid) 50㎍/㎖을 첨가하여 콜라겐 합성을 촉진시킨다. 배양 후 각 웰을 세척하고 시럼(serum)이 함유되지 않은 디엠이엠 배지로 교체한 후 24시간 더 배양한다. 배양 후 각 웰의 상층액을 모아 프로콜라겐 타입 아이 씨-펩타이드(Procollagen Type I C-peptide : PICP) 양을 키트(Kit) (Takara, Kyoto, Japan)을 이용하여 새로 합성된 콜라겐 양으로 PICP 양으로 측정하여, PICP 양을 ng/2x104세포로 환산하였다.Human Normal fibroblasts are seeded in 96-well microplates (2 × 10 4 cells / well) and incubated for 24 hours. After incubation the medium is replaced with DMEM without serum. At this time, put the hazelnut extract of various concentrations with the medium and incubated for 48 hours. Hazelnut extract was prepared in Example 8. Collagen synthesis is promoted by adding 50 μg / ml of ascorbic acid before the last 24 hours of culture. After incubation, each well is washed, replaced with DM medium containing no serum, and further incubated for 24 hours. After incubation, the supernatant of each well was collected, and the amount of procollagen type I C-peptide (PICP) was converted into PICP amount by the amount of collagen newly synthesized using Kit (Takara, Kyoto, Japan). As measured by, the amount of PICP was converted into ng / 2 × 10 4 cells.
2) 실험 결과2) Experiment result
개암풀 추출물은 인체 정상 섬유아세포에서 콜라겐 I의 합성 효과를 나타내었다. 실험 결과는 표 3에 제시된다.Hazelnut extract showed a synthetic effect of collagen I in human normal fibroblasts. The experimental results are shown in Table 3.
3. 개암풀 추출물의 세포증식 효과 실험3. Experiment of Cell Proliferation Effect of Hazelnut Extract
1) 실험방법1) Experiment Method
실험예 1의 방법과 동일하게 실험하였다. 개암풀 추출물은 실험예 8에서 재조한 것을 사용하였다.The experiment was carried out in the same manner as in Experiment 1. Hazelnut extract was prepared in Experimental Example 8.
2) 실험 결과2) Experiment result
개암풀 추출물은 인체 정상 섬유아세포에서 뚜렷한 세포 증식 효과를 나타내었으며 그 결과는 표 4에 기재된 바와 같다.Hazelnut extract showed a pronounced cell proliferation effect in human normal fibroblasts and the results are shown in Table 4.
5. 개암풀 추출물의 히아루론산 합성 증진 효과 실험5. Experimental Effect of Hyaluronic Acid Synthesis of Hazelnut Extract
1) 실험 방법1) Experiment Method
인체정상 섬유아세포(Human Normal fibroblast)를 6-웰 배양 플레이트에 접종시키고 (3x104 세포/웰) 48시간 배양한다. 이때 배지는 10% FCS (Fetal calf serum), 페니실린, 스트렙토마이신 (100㎍/㎖)등이 함유된 디엠이엠 배지를 사용하였다. 배양후 여러 농도의 개암풀 추출물이 함유된 배지로 교체하고 24시간 배양한다. 개암풀 추출물은 실시예 8에서 제조한 것을 사용하였다. 배양 후 배지 부분만 모으고 단백질을 제거하기 위해서 트리클로로아세트산(trichloroacetic aicd)를 최종농도 10%가 되게 넣고 24시간 4℃에서 보관한다. 이 용액을 원심분리하여 상층액을 투석(dialysis)하고 NaCl을 처리하여 최종농도 0.04M이 되도록 한 후 세틸피리디움 클로라이드(cetylpyridium chloride)를 첨가하여 히아루론산을 침전시킨다. 원심분리하여 침전물을 4M NaCl에 용해시키고, 에탄올에 재침전 시킨후 이 침전물을 정제수에 용해시킨다. 히아루론산을 정량하기 위하여 셀루로오스 아세테이트 스트립(Cellulose acetate strip)을 이용하여 전기영동한다 [참조: Hata, R. &Nagai, Y.(1972) Anal. Biochem. 45, 462-468]. 전기영동 후 0.5% 알시안 블루(Alcian blue)가 함유된 3% 아세트산에 침지 시킨 후 세척. 건조하여 600nm의 스캐너로 그 양을 측정한다.Human Normal fibroblasts are seeded in 6-well culture plates (3 × 10 4 cells / well) and incubated for 48 hours. In this case, DM medium containing 10% FCS (Fetal calf serum), penicillin, streptomycin (100 µg / ml) and the like was used. After incubation, the medium is replaced with medium containing hazelnut extract of various concentrations and incubated for 24 hours. Hazelnut extract was prepared in Example 8. After incubation, only the media portion is collected and trichloroacetic aicd is added to a final concentration of 10% in order to remove proteins and stored at 4 ° C for 24 hours. Centrifugation of this solution to dialysis (dialysis) of the supernatant, and treated with NaCl to a final concentration of 0.04M and then to the cetylpyridium chloride (cetylpyridium chloride) is added to precipitate hyaluronic acid. The precipitate is dissolved in 4M NaCl by centrifugation, reprecipitated in ethanol and the precipitate is dissolved in purified water. To quantify hyaluronic acid, electrophoresis is performed using a Cellulose acetate strip. Hata, R. & Nagai, Y. (1972) Anal. Biochem. 45, 462-468. After electrophoresis, immersed in 3% acetic acid containing 0.5% Alcian blue and washed. Dry and measure the amount with a 600 nm scanner.
2) 실험결과2) Experiment result
개암풀추출물은 인체정상 섬유아세포에서 히아루론산 합성증진효과를 나타내었으며 그 결과는 표 5에 기재된 바와 같다.Hazelnut extract showed a hyaluronic acid synthesis-promoting effect in human normal fibroblasts, and the results are shown in Table 5.
6. 개암풀 추출물 함유 화장료 조성물의 처방6. Prescription of cosmetic composition containing hazelnut extract
표 6 내지 11에 나타낸 바와 같은 처방으로 다양한 화장료 조성물을 제조하였다. 표 6은 유연화장수, 표7은 밀크로션, 표 8은 영양크림, 표 9는 에센스, 표 10은 맛사지 크림, 표 11은 팩의 처방을 각각 나타낸 것이다.Various cosmetic compositions were prepared by the prescription as shown in Tables 6-11. Table 6 is a soft cosmetics, Table 7 is a milk lotion, Table 8 is a nutrition cream, Table 9 is an essence, Table 10 is a massage cream, Table 11 shows a prescription of the pack.
이상 설명한 바와 같이, 본 발명에 따라 개암풀 추출물을 함유하는 화장료 조성물은 개암풀 추출물에 의한 세포증식효과, 콜라겐 합성효과 및 히아루론산 합성 효과로 인하여 여성호르몬의 결핍으로 인한 피부노화를 억제하는 효과를 제공하는 고부가가치의 신규, 유용의 발명인 것이다.As described above, the cosmetic composition containing hazelnut extract according to the present invention provides the effect of inhibiting skin aging due to the deficiency of female hormones due to the cell proliferation effect, collagen synthesis effect and hyaluronic acid synthesis effect by hazelnut extract It is a high value-added novel and useful invention.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000030873A KR20010110001A (en) | 2000-06-05 | 2000-06-05 | Cosmetics composition containing Psoralea corylifolia L. extracts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000030873A KR20010110001A (en) | 2000-06-05 | 2000-06-05 | Cosmetics composition containing Psoralea corylifolia L. extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010110001A true KR20010110001A (en) | 2001-12-12 |
Family
ID=45927640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020000030873A Ceased KR20010110001A (en) | 2000-06-05 | 2000-06-05 | Cosmetics composition containing Psoralea corylifolia L. extracts |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20010110001A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012134165A3 (en) * | 2011-03-28 | 2013-03-07 | 주식회사 한국전통의학연구소 | Composition for lung cancer treatment and composition for cosmetics containing psoraleae semen extract |
| US20130156873A1 (en) * | 2011-12-19 | 2013-06-20 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| CN103919141A (en) * | 2013-01-15 | 2014-07-16 | 宋济民 | Phaseolus vulgaris seed extract and preparation method and application thereof |
| US10500152B2 (en) | 2014-03-10 | 2019-12-10 | Mary Kay Inc. | Skin lightening compositions |
| US10682381B2 (en) | 2009-04-27 | 2020-06-16 | Mary Kay Inc. | Botanical formulations |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1171231A (en) * | 1997-08-28 | 1999-03-16 | Maruzen Pharmaceut Co Ltd | Skin whitening agent and skin whitening cosmetic |
| KR20000007648A (en) * | 1998-07-06 | 2000-02-07 | 서경배 | Cyclooxygenase-2 obstruction containing psoralea corylifolia extracts/or bakuchiol as effective component and anti-inflammation cosmetic material containing psoralea corylifolia extracts/or bakuchiol |
| KR20010026175A (en) * | 1999-09-03 | 2001-04-06 | 서경배 | whitening composition including the natural plant extract |
-
2000
- 2000-06-05 KR KR1020000030873A patent/KR20010110001A/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1171231A (en) * | 1997-08-28 | 1999-03-16 | Maruzen Pharmaceut Co Ltd | Skin whitening agent and skin whitening cosmetic |
| KR20000007648A (en) * | 1998-07-06 | 2000-02-07 | 서경배 | Cyclooxygenase-2 obstruction containing psoralea corylifolia extracts/or bakuchiol as effective component and anti-inflammation cosmetic material containing psoralea corylifolia extracts/or bakuchiol |
| KR20010026175A (en) * | 1999-09-03 | 2001-04-06 | 서경배 | whitening composition including the natural plant extract |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10682381B2 (en) | 2009-04-27 | 2020-06-16 | Mary Kay Inc. | Botanical formulations |
| US10953058B2 (en) | 2009-04-27 | 2021-03-23 | Mary Kay Inc. | Botanical formulations |
| US11638735B2 (en) | 2009-04-27 | 2023-05-02 | Mary Kay Inc. | Botanical formulations |
| US12268721B2 (en) | 2009-04-27 | 2025-04-08 | Mary Kay Inc. | Botanical formulations |
| WO2012134165A3 (en) * | 2011-03-28 | 2013-03-07 | 주식회사 한국전통의학연구소 | Composition for lung cancer treatment and composition for cosmetics containing psoraleae semen extract |
| US20130156873A1 (en) * | 2011-12-19 | 2013-06-20 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| US9138401B2 (en) * | 2011-12-19 | 2015-09-22 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| US9861573B2 (en) | 2011-12-19 | 2018-01-09 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| US10780041B2 (en) | 2011-12-19 | 2020-09-22 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| US11865202B2 (en) | 2011-12-19 | 2024-01-09 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
| CN103919141A (en) * | 2013-01-15 | 2014-07-16 | 宋济民 | Phaseolus vulgaris seed extract and preparation method and application thereof |
| US10500152B2 (en) | 2014-03-10 | 2019-12-10 | Mary Kay Inc. | Skin lightening compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120107427A1 (en) | Composition for promoting adipocyte differentiation containing an extract of rehmannia glutinosa, licorice, coicis semen, hordei fructus, chaenomelis fructus, acanthopanacis cortex or puerariae radix | |
| KR101393007B1 (en) | Cosmetic Composition for Skin-aging Protection and Wrinkle Improvement Comprising the Extract of Nephelium lappaceum and Litchi chinensis sonn as Active Ingredient | |
| KR102368903B1 (en) | A composition for increasing the thickness of eyelashes, eyebrows and hair and promoting growth | |
| KR100574848B1 (en) | Cosmetic composition containing kidney bean extract | |
| KR102817536B1 (en) | Natural licorice extract with anti-inflammatory effect, centella asiatica extract and plant-based squalane complex cosmetic composition with moisturizing effect | |
| KR20030025067A (en) | Composition of cosmetics contains punica extracts | |
| KR20140018666A (en) | Composition for skin external application containing fermented soybean extract | |
| KR101852252B1 (en) | Method for culturing Lilium Candidum Cell and Functional skin external application comprising Lilium Candidum Cell Culture Extract | |
| KR20010110001A (en) | Cosmetics composition containing Psoralea corylifolia L. extracts | |
| KR100467081B1 (en) | Cosmetic Composition for Improving Skin Wrinkles Comprising Bergenia Emeiensis as Active Ingredient | |
| KR20080093500A (en) | Roe deer urine extract | |
| KR20170045927A (en) | Anti-aging composition for skin external application comprising Potentilla chinensis Extract and Method for Preparing the Same | |
| KR100678864B1 (en) | Cosmetic composition for skin whitening containing cheongung extract and carnitine as active ingredients | |
| KR100702331B1 (en) | Cosmetic composition for improving skin wrinkles containing Baekchulchae extract as an active ingredient | |
| KR100467501B1 (en) | A cosmetic composite | |
| KR20010092070A (en) | Skin elasticity-improving cosmetic composition comprising Chestnut inner bark extract and Malt extract | |
| KR100946584B1 (en) | Cosmetic composition for astringent and skin irritation containing fruit extract and Blue Lotus extract | |
| KR102908981B1 (en) | Cosmetic Composition for Improving Skin Wrinkle Comprising Extract of Mallotusjaponicus and Peptide Complex | |
| KR20030087236A (en) | Cosmetic Composition for Skin-Whitening Comprising Extract of Cnidium officinale | |
| KR20180062712A (en) | Cosmetic composition comprising an extract of Phaseolus vulgaris L. | |
| KR102831553B1 (en) | Cosmetic compositions for brightening skin and shoothing skin comprising phytolight, lactate and boerhavia diffusa root extract as active ingredients | |
| KR20020001914A (en) | Cosmetics containing Ramulus mori extracts and glutathione for skin whitening | |
| KR20070111635A (en) | Wrinkle improvement cosmetic composition containing extract of distant tree as an active ingredient | |
| KR20090101596A (en) | Cosmetic composition for reducing the skin wrinkle comprising the extract of securinega suffruticosa as active ingredient | |
| KR20020046614A (en) | Skin whitening composition containing the fruit extracts of forsythia suspensa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |